Aurealis Therapeutics team visited China from June 9–13, 2025, for a dedicated partnering week. Juha Yrjänheikki (CEO), Laurent Décory (COO), Hanna-Riikka Kärkkäinen (Director, Quality & Regulatory Affairs), and Jere Kurkipuro (Director, Pre-clinical & Pharmacology) met with investors, scientific partners, and licensing stakeholders to explore new collaboration opportunities.
Week of Strategic Meetings in China 2025
During the week of 20–25 October 2025, Aurealis Therapeutics’ CEO Juha Yrjänheikki and COO Laurent Décory traveled to Beijing, Shanghai and Hong Kong for a series of high-level meetings with key stakeholders, investors, and potential partners. The visit aimed to strengthen strategic relationships that support the development and commercialisation of Aurealis’ multi-target cell and gene therapy candidates, AUP-16 for chronic